Grifols SA
GRFS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001438569
No open-market purchases or sales by Grifols SA insiders were filed in the last 90 days; 164 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Grifols SA changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 181 | 3 | 182 | +4 |
| Shares | 140.2M | 32.8K | 143.4M | +3.32M (+2.4%) |
| Value | $1.40B | $326.5K | $1.34B | −$54.5M (−3.9%) |
3 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (30)
Institutions that held Grifols SA at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (26)
Institutions that held Grifols SA at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (3)
Institutions that held Grifols SA at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Shilanski & Associates, Inc. | 25,044 | $249.4K |
| Cubist Systematic Strategies, LLC | 5,447 | $54.3K |
| Point72 Asia (Singapore) Pte. Ltd. | 2,286 | $22.8K |